<DOC>
	<DOC>NCT01990859</DOC>
	<brief_summary>The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma</brief_summary>
	<brief_title>Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Histologically or cytologically confirmed diagnosis of malignant melanoma Previouslytreated or untreated unresectable Stage III or Stage IV melanoma Measurable/evaluable disease per modified World Health Organization (mWHO) criteria, within 28 days of first dose of study drug Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Active brain metastases Primary ocular or mucosal melanoma History of or current active autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>